stockrow
Friday 6 November 2026
Export BIOA’s income statement to Excel — free account
BioAge Labs, Inc.
BIOA Healthcare Drug Manufacturers Specialty & Generic
BioAge Labs, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million.
- Revenue
- −85.5%
- EPS
- −30.4%
- Free cash flow
- −92.8%
- Total debt
- −83.6%
Quarter to September 2026, against a year earlier
5.30
0.24
−4.33%
Follow BIOA
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
52.85 | 72.02 | 106.13 | 37.85 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(16.83) | (30.90) | (57.06) | (10.51) | |
P/B ratio |
1.75 | 1.96 | 2.93 | 0.94 | |
Price to Tangible BV |
1.75 | 1.96 | 2.93 | 0.94 | |
EV/Sales |
22.01 | 35.09 | 75.56 | 1.04 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.43) | (4.10) | (8.93) | (0.09) | |
EV/FCF |
(0.84) | (1.49) | (3.22) | (0.03) | |
Quick Ratio |
14.00 | 24.26 | 16.62 | 0.03 | |
Current Ratio |
14.24 | 24.76 | 17.19 | 15.51 | |
Net Debt/EBITDA |
9.82 | 15.09 | 10.89 | 0.00 | |
Debt/Assets |
0.90% | 0.29% | 0.00% | 0.00% | |
Debt/Equity |
0.01 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.03 | 0.03 | 0.03 | 0.03 | |
Operating CF/Net income |
1.09 | 1.08 | 0.74 | 0.92 | |
Capex/Depreciation |
(2,244.33) | (0.41) | (4.69) | (0.22) | |
Interest Coverage |
(308.95) | (650.64) | (29,333.00) | — | |
Research and Development Expense of Revenue |
795.97% | 736.29% | 994.08% | 10,145.30% | |
Selling, General and Administrative Expense of Revenue |
227.45% | 279.11% | 302.69% | 2,508.72% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
88.43% | 153.54% | 174.17% | 1,558.39% | |
Graham Net Nets |
0.56 | 0.50 | 0.28 | 0.84 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(16.93%) | (13.72%) | (9.71%) | (35.97%) | |
Free Cash Flow Yield |
(49.87%) | (32.76%) | (22.10%) | (79.18%) | |
Revenue per Share |
0.09 | 0.07 | 0.05 | 0.01 | |
Operating CF per Share |
(0.79) | (0.57) | (0.43) | (0.67) | |
Capex per Share |
(4.31) | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(5.10) | (0.57) | (0.44) | (0.67) | |
Cash per Share |
7.82 | 9.02 | 7.11 | 0.00 | |
Shareholders Equity per Share |
7.57 | 8.92 | 8.36 | 7.55 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.57 | 8.92 | 8.36 | 7.55 | |
Free Cash Flow |
(183.11) | (24.07) | (19.59) | (30.98) | |
Working Capital |
266.66 | 376.03 | 311.10 | 276.03 | |
Capital Expenditures |
(154.86) | (0.03) | (0.33) | (0.02) | |
Net Current Asset Value |
263.96 | 373.33 | 308.30 | 273.85 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
50.31 | 0.01 | 0.13 | 0.06 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 0.54 | 0.61 | 0.54 | |
Average Payables |
2.34 | 3.53 | 3.49 | 3.46 | |
Average Assets |
326.56 | 370.75 | 359.54 | 336.37 | |
Average Common Equity |
297.59 | 346.14 | 334.85 | 311.96 |
Columns are period end dates · fundamentals updated 5 Nov 2026